Since glioblastoma cases negative for IDH1 mutation tend to be those primary and more aggressive glioblastomas [21], we evaluated the presence of IDH1–R132H mutation by immunohistochemistry in order to verify if the tumor cells injected in mouse brain tissue were able to maintain this same characteristic from the original tumor. This evidence concerns the gene IDH1 and neoplasm.